Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fibrillation and Permanent Pacemaker

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fibrillation and Permanent Pacemaker

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs NTC 801 (Primary)
  • Indications Paroxysmal atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2012 Planned end date changed from 1 Mar 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 21 Apr 2012 Planned number of patients changed from 20 to 50 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top